NASDAQ:BGLC
BioNexus Gene Lab Corp
BioNexus Gene Lab Corp's revenue fell 21.9% in fiscal 2025 to $7.4M while operating margin fell to −39.9%. Free cash flow was −$1.9M, −25.3% of revenue.Summary generated from BioNexus Gene Lab Corp's SEC filings. Latest annual report filed Apr 14, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$7.4M
Revenue growth−21.9%
Revenue, 5-yr CAGR−8.2%
Gross margin14.6%
Operating margin−39.9%
Net margin−40.2%
ROICn/a
Return on equity−35.2%
Debt / equityn/a
Free cash flow−$1.9M
FCF margin−25.3%
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 13 | 11 | 10 | 10 | 7 |
| Operating income | 1 | −0 | −3 | −2 | −3 |
| Net income | 1 | −0 | −3 | −2 | −3 |
| Free cash flow | 0 | 1 | −2 | −2 | −2 |
Recent filings
- 8-KEntry into a material agreement
Oct 7, 2026 - 4Insider transaction report
Aug 14, 2026 - 4Insider transaction report
Aug 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KOther events
Jul 28, 2026 - 8-KOther events
Jun 5, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 15, 2026 - 10-KAnnual report for the fiscal year ended Dec 31, 2025
Apr 14, 2026